vimarsana.com

Page 159 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cellular Biomedicine Group, Inc Announces Completion of Merger

Share this article Share this article ROCKVILLE, Md. and SHANGHAI, Feb. 19, 2021 /PRNewswire/ Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ( CBMG or the Company ) today announced the completion of the merger (the Merger ) of the Company with CBMG Merger Sub Inc., a Delaware corporation ( Merger Sub ) and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands ( Parent ), pursuant to the previously announced Agreement and Plan of Merger (the Merger Agreement ), dated as of August 11, 2020, by and among the Company, Parent and Merger Sub. Under the terms of the Merger Agreement, which was approved by the Company s stockholders at its special meeting of stockholders held on February 8, 2021, each share of the Company s common stock, par value $0.001 per share (the Company Common Stock ), issued and outstanding immediately prior to the effective time of the Merger (the Effective Time ), other

Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Year-End Report, 2020 Positive Topline Results from Pivotal Phase 3 NefIgArd Trial “On November 8, 2020, we announced positive topline readout of Part A of our Phase 3 pivotal trial, NefIgArd. The results were statistically significant and clinically relevant: proteinuria showed a 31% reduction versus baseline, a stronger effect than what was seen in the Phase 2b (27%), which is generally not expected when moving from Phase 2 to Phase 3. In addition, eGFR was stabilised in the treated patient population, which in the end is the true treatment goal. This potentially disease modifying effect is to our knowledge unique to Nefecon, which we find extremely exciting, and we look forward to our interactions with regulators during the year as we progress towards potential approval.

Semtech and WITRAC Provide Cold Chain Control for Maritime Corridor With LoRaWAN® – Consumer Electronics Net

2 months ago The LoRaWAN protocol tracks and improves the transportation of fresh goods from Spain to Canary Islands CAMARILLO, Calif.–(BUSINESS WIRE)–Semtech Corporation (Nasdaq: SMTC), a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms, announced that WITRAC, a company developing solutions with real-time location and telemetry capabilities, has integrated the LoRaWAN® protocol and LoRa® 2.4GHz into its global track and trace platform to provide customers with full control and traceability of assets in the supply chain. “Semtech’s LoRa devices have been instrumental in supporting WITRAC’s mission to re-evolve and digitize Industry 4.0 through visibility, traceability, control, and efficiency,” said Javier Ferrer, CEO of WITRAC. “Our customers and their stakeholders have the ability to guarantee delivery times and maintain appropriate temperature conditions of fresh food transport i

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.